|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Randall JM, Millard F and Kurzrock R:
Molecular aberrations, targeted therapy, and renal cell carcinoma:
Current state-of-the-art. Cancer Metastasis Rev. 33:1109–1124.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ and Russo P: Systemic therapy
for renal cell carcinoma. J Urol. 163:408–417. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with
meta-static renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goto Y, Kurozumi A, Enokida H, Ichikawa T
and Seki N: Functional significance of aberrantly expressed
microRNAs in prostate cancer. Int J Urol. 22:242–252. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nishikawa R, Chiyomaru T, Enokida H,
Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa
M and Seki N: Tumour-suppressive microRNA-29s directly regulate
LOXL2 expression and inhibit cancer cell migration and invasion in
renal cell carcinoma. FEBS Lett. 589:2136–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa
M, et al: MicroRNA-218 inhibits cell migration and invasion in
renal cell carcinoma through targeting caveolin-2 involved in focal
adhesion pathway. J Urol. 190:1059–1068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshino H, Enokida H, Itesako T, Tatarano
S, Kinoshita T, Fuse M, Kojima S, Nakagawa M and Seki N:
Epithelial-mesenchymal transition-related microRNA-200s regulate
molecular targets and pathways in renal cell carcinoma. J Hum
Genet. 58:508–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamada Y, Hidaka H, Seki N, Yoshino H,
Yamasaki T, Itesako T, Nakagawa M and Enokida H: Tumor-suppressive
microRNA-135a inhibits cancer cell proliferation by targeting the
c-MYC oncogene in renal cell carcinoma. Cancer Sci. 104:304–312.
2013. View Article : Google Scholar
|
|
16
|
Yoshino H, Enokida H, Itesako T, Kojima S,
Kinoshita T, Tatarano S, Chiyomaru T, Nakagawa M and Seki N:
Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in
renal cell carcinoma. Cancer Sci. 104:1567–1574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishihara T, Seki N, Inoguchi S, Yoshino H,
Tatarano S, Yamada Y, Itesako T, Goto Y, Nishikawa R, Nakagawa M,
et al: Expression of the tumor suppressive miRNA-23b/27b cluster is
a good prognostic marker in clear cell renal cell carcinoma. J
Urol. 192:1822–1830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kikkawa N, Hanazawa T, Fujimura L, Nohata
N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki
N: miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
103:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukumoto I, Hanazawa T, Kinoshita T,
Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida
H, Nakagawa M, et al: MicroRNA expression signature of oral
squamous cell carcinoma: Functional role of microRNA-26a/b in the
modulation of novel cancer pathways. Br J Cancer. 112:891–900.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kato M, Goto Y, Matsushita R, Kurozumi A,
Fukumoto I, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M,
Ichikawa T, et al: MicroRNA-26a/b directly regulate La-related
protein 1 and inhibit cancer cell invasion in prostate cancer. Int
J Oncol. 47:710–718. 2015.PubMed/NCBI
|
|
21
|
Kinoshita T, Hanazawa T, Nohata N, Kikkawa
N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto
Y, et al: Tumor suppressive microRNA-218 inhibits cancer cell
migration and invasion through targeting laminin-332 in head and
neck squamous cell carcinoma. Oncotarget. 3:1386–1400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gilkes DM, Semenza GL and Wirtz D: Hypoxia
and the extracellular matrix: Drivers of tumour metastasis. Nat Rev
Cancer. 14:430–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kurozumi A, Goto Y, Matsushita R, Fukumoto
I, Kato M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa
T, et al: Tumor-suppressive microRNA-223 inhibits cancer cell
migration and invasion by targeting ITGA3/ITGB1 signaling in
prostate cancer. Cancer Sci. 107:84–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wiemer EA: The role of microRNAs in
cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Singh SK, Pal Bhadra M, Girschick HJ and
Bhadra U: MicroRNAs - micro in size but macro in function. FEBS J.
275:4929–4944. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fuse M, Kojima S, Enokida H, Chiyomaru T,
Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M,
et al: Tumor suppressive microRNAs (miR-222 and miR-31) regulate
molecular pathways based on microRNA expression signature in
prostate cancer. J Hum Genet. 57:691–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y,
Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and
motility in bladder cancer by targeting HMGA1. FEBS Lett.
587:2467–2473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang B, Liu XX, He JR, Zhou CX, Guo M, He
M, Li MF, Chen GQ and Zhao Q: Pathologically decreased miR-26a
antagonizes apoptosis and facilitates carcinogenesis by targeting
MTDH and EZH2 in breast cancer. Carcinogenesis. 32:2–9. 2011.
View Article : Google Scholar
|
|
30
|
Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang
JR, Zeng C and Zhuang SM: MicroRNA-26a/b and their host genes
cooperate to inhibit the G1/S transition by activating the pRb
protein. Nucleic Acids Res. 40:4615–4625. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koh CM, Iwata T, Zheng Q, Bethel C,
Yegnasubramanian S and De Marzo AM: Myc enforces overexpression of
EZH2 in early prostatic neoplasia via transcriptional and
post-transcriptional mechanisms. Oncotarget. 2:669–683. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang SW, Chang WH, Su YC, Chen YC, Lai YH,
Wu PT, Hsu CI, Lin WC, Lai MK and Lin JY: MYC pathway is activated
in clear cell renal cell carcinoma and essential for proliferation
of clear cell renal cell carcinoma cells. Cancer Lett. 273:35–43.
2009. View Article : Google Scholar
|
|
33
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
34
|
Barker HE, Cox TR and Erler JT: The
rationale for targeting the LOX family in cancer. Nat Rev Cancer.
12:540–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kagan HM and Li W: Lysyl oxidase:
Properties, specificity, and biological roles inside and outside of
the cell. J Cell Biochem. 88:660–672. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vadasz Z, Kessler O, Akiri G,
Gengrinovitch S, Kagan HM, Baruch Y, Izhak OB and Neufeld G:
Abnormal deposition of collagen around hepatocytes in Wilson's
disease is associated with hepatocyte specific expression of lysyl
oxidase and lysyl oxidase like protein-2. J Hepatol. 43:499–507.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim YM, Kim EC and Kim Y: The human lysyl
oxidase-like 2 protein functions as an amine oxidase toward
collagen and elastin. Mol Biol Rep. 38:145–149. 2011. View Article : Google Scholar
|
|
38
|
Fong SF, Dietzsch E, Fong KS, Hollosi P,
Asuncion L, He Q, Parker MI and Csiszar K: Lysyl oxidase-like 2
expression is increased in colon and esophageal tumors and
associated with less differentiated colon tumors. Genes Chromosomes
Cancer. 46:644–655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peinado H, Moreno-Bueno G, Hardisson D,
Pérez-Gómez E, Santos V, Mendiola M, de Diego JI, Nistal M,
Quintanilla M, Portillo F, et al: Lysyl oxidase-like 2 as a new
poor prognosis marker of squamous cell carcinomas. Cancer Res.
68:4541–4550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu LX, Jiang HC, Liu ZH, Zhou J, Zhang
WH, Zhu AL, Wang XQ and Wu M: Integrin gene expression profiles of
human hepatocellular carcinoma. World J Gastroenterol. 8:631–637.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kinoshita T, Nohata N, Hanazawa T, Kikkawa
N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto
Y, et al: Tumour-suppressive microRNA-29s inhibit cancer cell
migration and invasion by targeting laminin-integrin signalling in
head and neck squamous cell carcinoma. Br J Cancer. 109:2636–2645.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yamamoto N, Kinoshita T, Nohata N, Itesako
T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N: Tumor
suppressive microRNA-218 inhibits cancer cell migration and
invasion by targeting focal adhesion pathways in cervical squamous
cell carcinoma. Int J Oncol. 42:1523–1532. 2013.PubMed/NCBI
|
|
43
|
Gordon MK and Hahn RA: Collagens. Cell
Tissue Res. 339:247–257. 2010. View Article : Google Scholar :
|
|
44
|
Hase H, Jingushi K, Ueda Y, Kitae K, Egawa
H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, et
al: LOXL2 status correlates with tumor stage and regulates integrin
levels to promote tumor progression in ccRCC. Mol Cancer Res.
12:1807–1817. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schietke R, Warnecke C, Wacker I, Schödel
J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J,
Eckardt KU, et al: The lysyl oxidases LOX and LOXL2 are necessary
and sufficient to repress E-cadherin in hypoxia: Insights into
cellular transformation processes mediated by HIF-1. J Biol Chem.
285:6658–6669. 2010. View Article : Google Scholar :
|
|
46
|
Moon HJ, Finney J, Xu L, Moore D, Welch DR
and Mure M: MCF-7 cells expressing nuclear associated lysyl
oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal
transition (EMT) phenotype and are highly invasive in vitro. J Biol
Chem. 288:30000–30008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
van der Slot AJ, Zuurmond AM, van den
Bogaerdt AJ, Ulrich MM, Middelkoop E, Boers W, Karel Ronday H,
DeGroot J, Huizinga TW and Bank RA: Increased formation of
pyridinoline cross-links due to higher telopeptide lysyl
hydroxylase levels is a general fibrotic phenomenon. Matrix Biol.
23:251–257. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gilkes DM, Bajpai S, Wong CC, Chaturvedi
P, Hubbi ME, Wirtz D and Semenza GL: Procollagen lysyl hydroxylase
2 is essential for hypoxia-induced breast cancer metastasis. Mol
Cancer Res. 11:456–466. 2013. View Article : Google Scholar : PubMed/NCBI
|
